Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2026
Date of Filing: May 13, 2026
The registrant filed this report to incorporate by reference a press release dated May 13, 2026, regarding clinical trial progress for its drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves solely to disseminate a press release and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change reported is the advancement of the drug candidate Namodenoson into a Phase 2b combination study with immunotherapy. This decision follows positive data from a Phase 2a study in pancreatic cancer.
Guidance, Outlook, and Management Commentary
- Clinical Progress: Management announced the transition of Namodenoson from Phase 2a to Phase 2b based on positive results in pancreatic cancer.
- Study Design: The upcoming Phase 2b study will evaluate Namodenoson in combination with immunotherapy.
- Outlook: The filing indicates continued development momentum for the company's lead asset.
- Risks and Contingencies: The filing text does not explicitly detail specific risks or contingencies beyond the inherent uncertainties of clinical development implied by the trial progression.
Investor Verification Checklist
- Verify the specific positive data points from the Phase 2a pancreatic cancer study referenced in the press release (Exhibit 99.1).
- Confirm the design, endpoints, and enrollment timeline for the new Phase 2b combination study.
- Review the company's cash runway and capital requirements to support the Phase 2b trial, as this filing does not disclose current liquidity.
- Assess the regulatory implications of combining Namodenoson with immunotherapy.